

Funder	Project Title	Funding	Institution
Department of Defense - Autism Research Program	Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial	\$0	University of Medicine & Dentistry of New Jersey - Robert Wood Johnson Medical School
Department of Defense - Autism Research Program	Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial	\$0	University of Medicine & Dentistry of New Jersey
Department of Defense - Autism Research Program	Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial	\$0	University of Medicine & Dentistry of New Jersey - Robert Wood Johnson Medical School
Autism Speaks	Association of cholinergic system dysfunction with autistic behavior in fragile X syndrome: Pharmacologic and imaging probes	\$91,292	Stanford University
Autism Speaks	Randomized phase 2 trial of RAD001 (an mTOR inhibitor) in patients with tuberous sclerosis complex	\$65,000	Boston Children's Hospital
Autism Speaks	Clinical Trials Network	\$0	Autism Speaks (AS)
Autism Speaks	A multi-site double-blind placebo-controlled trial of memantine vs. placebo in children with autism	\$97,238	Holland Bloorview Kids Rehabilitation Hospital
Health Resources and Services Administration	Controlled trial of sertraline in young children with Fragile X Syndrome	\$285,177	University of California, Davis
National Institutes of Health	ACE Center: Understanding repetitive behavior in autism	\$257,803	University of California, Los Angeles
National Institutes of Health	ACE Center: The pharmacogenetics of treatment for insistence sameness in autism	\$378,379	University of Illinois at Chicago
National Institutes of Health	Trial of a glutamate antagonist in the treatment of OCD and autistic disorders	\$352,969	National Institutes of Health
Simons Foundation	Testing the use of helminth worm ova in treating autism spectrum disorders	\$0	Montefiore Medical Center